Press Releases

Date Title and Summary
Toggle Summary Kezar Life Sciences Closes $23M Series A Financing
Startup to Spin Out Assets From Amgen Subsidiary Onyx, Focus on Innovative New Treatments for Autoimmune Disorders SOUTH SAN FRANCISCO, Calif., June 16, 2015 /PRNewswire/ -- Kezar Life Sciences, a company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune
Toggle Summary Upstart Kezar wrangles $23M to pick up where Onyx left off